Comparative Pharmacology
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus SODIUM CHROMATE CR 51.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IODOHIPPURATE SODIUM I 131 versus SODIUM CHROMATE CR 51.
IODOHIPPURATE SODIUM I 131 vs SODIUM CHROMATE CR 51
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodohippurate sodium I 131 is a radioactive diagnostic agent that is actively transported by the renal tubules, allowing imaging of renal morphology and function. The iodine-131 emits gamma radiation, enabling scintigraphic evaluation of renal blood flow, tubular secretion, and excretion.
Radiolabeled sodium chromate (51Cr) binds to red blood cells, tagging them for survival studies. 51Cr emits gamma radiation, allowing detection and quantification of RBC mass and survival via scintillation counting or imaging.
Adult: 5-30 microcuries (0.185-1.11 MBq) intravenously for renal function studies.
Intravenous injection, 5-30 microcuries (0.185-1.11 MBq) as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 60 minutes in patients with normal renal function. In renal impairment, half-life may be prolonged up to several hours, correlating with reduced clearance.
The biological half-life is approximately 27–30 days. Clinically, gradual clearance from blood and tissues occurs over weeks to months.
Primarily renal; >90% of administered dose excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Fecal excretion <2%.
Primarily renal. Approximately 90% of absorbed dose is excreted in urine within 48 hours. Fecal excretion accounts for less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical